REGENERX TO RECEIVE ITS FIRST DRUG PATENT IN CHINA

RegeneRx Biopharmaceuticals, Inc. reported that it received notification that the State Intellectual Property Office of the People's Republic of China (CSIPO) has allowed its first patent application for the Company's Thymosin beta 4 (TB4) wound healing technology platform in that country.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1126083XSL_NEWSML_TO_NEWSML_WEB.xml)